Last reviewed · How we verify
Insulin, Long-Acting and Insulin
At a glance
| Generic name | Insulin, Long-Acting and Insulin |
|---|---|
| Also known as | Humalin N(r), Humalog (r) |
| Sponsor | Sansum Diabetes Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin, Long-Acting and Insulin CI brief — competitive landscape report
- Insulin, Long-Acting and Insulin updates RSS · CI watch RSS
- Sansum Diabetes Research Institute portfolio CI